Cue Biopharma, Inc. CUE 深 滬
等待開盤 08-27 09:30:00 美东时间
0.84
+0.022
+2.66%
華盛通- 最 高0.8873
- 今 開0.8856
- 成交量 19.81万股
- 最 低 0.82
- 昨 收 0.8182
- 總市值 6329.39万
- 52周最高 1.9891
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.45
- 委 比 60.44%
- 總股本 7534.99万
- 歷史最高 31.69
- 量 比 1.37
- 振 幅 8.23%
- 歷史最低 0.45
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅17.9%！Stifel维持英伟达"买入"评级，目标价升至212美元；美银首予Figma"中性"评级，目标价85美元
今日重点评级关注：Stifel：维持英伟达"买入"评级，目标价从202美元升至212美元；蒙特利尔银行：维持Sabra Health Care REIT"与大市齐平"评级，目标价从19美元升至22美元
08-26 10:29
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Cantor Global Healthcare Conference in New York on September 5, 2025. The discussion will focus on updates from the Immuno-STAT® platform, including advancements in CUE-401, its lead autoimmune asset. Daniel Passeri, CEO, will present at 8:00 a.m. EDT, with a live and archiv...
08-21 12:00
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
Cue Biopharma launched a Phase 1b trial for CUE-102 targeting recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute. CUE-102, a therapeutic biologic, activates Wilms’ Tumor 1 (WT1)-specific T cells to combat WT1-expressing cancers. The study, led by David A. Reardon, MD, aims to assess tolerability and clinical activity in rGBM patients. WT1 is an oncofetal protein overexpressed in various cancers, and CUE-102 has shown anti-tu...
08-13 12:00
Cue Biopharma Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $2.954M Beat $2.396M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 55 percent increase over losses of $(0.20) per share from the
08-13 04:33
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Cue Biopharma在2025年第二季度取得了显著进展，包括收到FDA对CUE-401的IND反馈，与Boehringer Ingelheim达成合作协议开发CUE-501，筹集约$20 million，以及在HPV+ HNSCC患者中展示了CUE-101的潜力。财务方面，公司报告协作收入$3 million，研发和管理费用分别为$7.9 million和$3.7 million，净亏损$8.48 million。此外，公司举办了投资者活动，并在ASGCT年会上展示了CUE-101的初步数据。
08-12 20:05
Biocardia Provides Expected Timing For Regulatory Activities For FDA And Japan PMDA Approvals Of Its CardiAMP Cell Therapy System And Helix Transendocardial Delivery Catheter
Q3 2025 Helix application for approval to FDAThe Company intends to submit for approval of the Helix Transendocardial Delivery System (Helix) to FDA as a DeNovo 510(k) application based on its safety and performance in
08-04 18:02
Cue Energy Reports Strong Quarter with Strategic Developments
Cue Energy Resources Limited ( ($AU:CUE) ) has provided an announcement. Cue En...
07-24 10:27
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest...
07-23 21:26
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
Cue Biopharma reported additional complete response (CR) in a patient with recurrent metastatic HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and pembrolizumab. The overall response rate (ORR) reached 50% for patients with CPS ≥1, including 50% in low CPS (1-19). Twelve-month overall survival was 88%, and median overall survival (mOS) was 32 months, significantly outperforming historical data. The findings highlight the ...
07-16 12:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pluri (NASDAQ:PLUR) shares moved upwards by 24.0% to $5.99 during Tues...
07-02 05:05
